Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Neeraj GuptaHuyuan YangMichael J HanleySteven ZhangRachael LiuShaji KumarPaul G RichardsonTomas SkacelKarthik VenkatakrishnanPublished in: Targeted oncology (2018)
ClinicalTrials.gov NCT00932698, NCT00963820, NCT01217957, NCT01564537.